BMS-488043

BMS-488043 is an oral small-molecule HIV-1 attachment inhibitor developed by Bristol Myers Squibb. It acts by blocking the binding of the HIV envelope protein gp120 to CD4+ lymphocytes, thereby preventing viral entry into host cells. The drug is a member of a novel class of antiretrovirals known as HIV fusion inhibitors and specifically targets the early stage of viral entry. BMS-488043 demonstrated potent antiviral activity against various HIV-1 subtypes in vitro and in clinical studies showed dose-dependent reductions in plasma HIV RNA levels. Its mechanism involves noncompetitive inhibition at the CD4 binding pocket on gp120, interfering with conformational changes required for viral fusion[3][5][6][8]. Despite promising safety and pharmacokinetic profiles in early trials, development for HIV infection was discontinued[4][7].

Other names

phosphonoxymethyl bms 488043 prodrug